Eribulin mesylate combined with local treatment for brain metastasis from breast cancer: Two case reports

Kyung Do Byun, Sung Gwe Ahn, Hyung Joo Baik, Anbok Lee, Ki Beom Bae, Min Sung An, Kwang Hee Kim, Jae Ho Shin, Ha Kyoung Park, Heunglae Cho, Joon Jeong, Tae Hyun Kim

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metastatic breast cancers. However, these studies included few patients with brain metastases. Metastatic brain tumors (MBT) were detected during first-line palliative chemotherapy in a 43-year-old woman with breast cancer metastasis to the lung and mediastinal nodes; the genetic subtype was luminal B-like human epidermal growth factor receptor 2 (HER2)-negative. Whole brain radiotherapy (WBRT) followed by eribulin treatment continuously decreased the size, and induced regression, of the MBT with systemic disease stability for 12 months. Another 48-year-old woman with metastatic breast cancer (HER2+ subtype) presented with MBT. Following surgical resection of the tumor, eribulin with concurrent WBRT showed regression of the MBT without systemic progression for 18 months.

Original languageEnglish
Pages (from-to)214-217
Number of pages4
JournalJournal of Breast Cancer
Issue number2
Publication statusPublished - 2016 Jun

Bibliographical note

Publisher Copyright:
© 2016 Korean Breast Cancer Society. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Eribulin mesylate combined with local treatment for brain metastasis from breast cancer: Two case reports'. Together they form a unique fingerprint.

Cite this